We investigated the possible causative role of interleukin 6 (IL-6) in the paraneoplastic inflammatory syndrome and in paraneoplastic cholestasis (Stauffer syndrome) associated with renal-cell carcinoma in a series of 119 patients with metastases. IL-6 levels were found significantly higher in patie
β¦ LIBER β¦
Dexamethasone and interleukin-2 combination therapy for advanced renal cell carcinoma in a patient with paraneoplastic inflammatory syndrome
β Scribed by TOSHIAKI SHINOJIMA; MOTOTSUGU OYA; HIDAKA KOHNO; KEN MARUMO; MASARU MURAI
- Book ID
- 108976540
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 144 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0919-8172
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Role of interleukin-6 in the paraneoplas
β
Jean-Yves Blay; Jean-FranΓ§ois Rossi; John Wijdenes; Christine Menetrier-Caux; St
π
Article
π
1997
π
John Wiley and Sons
π
French
β 191 KB
π 2 views
Myositis associated with interleukin-2 t
β
Francisco J. Esteva-Lorenzo; John E. Janik; Robert G. Fenton; Alison Emslie-Smit
π
Article
π
1995
π
John Wiley and Sons
π
English
β 529 KB
Progressive anemia following combination
β
YUKINARI HOSOKAWA; TATSUKI KISHINO; TAKAMASA ONO; NOBUO OYAMA; KUNIO HAYASHI; HI
π
Article
π
2004
π
John Wiley and Sons
π
English
β 199 KB
GAD antibody positive paraneoplastic sti
β
John C. McHugh; Brian Murray; Radhakrishnan Renganathan; Sean Connolly; Tim Lync
π
Article
π
2007
π
John Wiley and Sons
π
English
β 121 KB
Polyethylene glycol conjugated interleuk
β
Ronald M. Bukowski; James Young; Gary Goodman; Frederick Meyers; Brian F. Issell
π
Article
π
1993
π
Springer US
π
English
β 487 KB
Thirteen-year, long-term efficacy of int
β
Jens Atzpodien; Reinhard Hoffmann; Marcus Franzke; Christian Stief; Thomas Wande
π
Article
π
2002
π
John Wiley and Sons
π
English
β 98 KB
## Background: The goal of the current report was to demonstrate the long-term efficacy of outpatient subcutaneous (sc) interferon alpha (ifn-alpha) and sc interleukin 2 (il-2)-based combination regimens in patients with metastatic renal cell carcinoma. ## Methods: In three consecutive clinical t